Scarica l'app Stockscreener
21.88
0.64%
0.14
Dopo l'orario di chiusura:
21.90
0.02
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$21.74
Aprire:
$21.66
Volume 24 ore:
2.30M
Relative Volume:
1.72
Capitalizzazione di mercato:
$2.10B
Reddito:
-
Utile/perdita netta:
$-804.34M
Rapporto P/E:
-2.3252
EPS:
-9.41
Flusso di cassa netto:
$-531.06M
1 W Prestazione:
+3.45%
1M Prestazione:
-20.87%
6M Prestazione:
-57.06%
1 anno Prestazione:
-45.07%
Intervallo 1D:
$20.68
$21.97
Intervallo di 1 settimana:
$17.42
$23.43
Portata 52W:
$15.79
$55.70
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Confronta BHVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
21.88 | 2.10B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Are Smart Investors Making the Right Decision? Biohaven Ltd (BHVN) - Sete News
BHVN’s Market Whiplash: -41.79% YTD Decline, -23.42% Plunge in 30 Days - investchronicle.com
Biohaven secures $600m financing as it awaits FDA prodrug decision - Yahoo Finance
Biohaven (NYSE:BHVN) Given New $57.00 Price Target at Robert W. Baird - Defense World
Biohaven (BHVN) Secures Up to $600M Investment from Oberland Cap - GuruFocus
BHVN’s price-to-cash ratio: Is it a good investment at the moment? - uspostnews.com
Why BioHaven Stock Is Soaring Today - Mitrade
A Guide To The Risks Of Investing In Biohaven Ltd (BHVN) - knoxdaily.com
Biohaven Ltd. Receives Buy Rating Amid Strategic EU Resubmission and Positive FDA Outlook - TipRanks
Biohaven secures up to $600 million from Oberland Capital - Investing.com
Biohaven Rallies On Heels Of $600M Funding Agreement With OberlandBiohaven (NYSE:BHVN) - Benzinga
Biohaven announces investment of up to $600M - Hartford Business Journal
Financial Analysis: Biohaven Ltd (BHVN)’s Ratios Unveil Key Insights - DWinneX
Biohaven Announces Investment by Oberland Capital - Contract Pharma
Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Biohaven Ltd. Secures $600M Investment from Oberland Capital - TipRanks
Biohaven Announces Investment Up To $600 Mln By Oberland Capital - marketscreener.com
Why Biohaven Ltd. Shares Are Tumbling - TipRanks
Biohaven Lands Major $600 Million Deal With Oberland Capital - Finimize
Biohaven Signs Deal for Investment of up to $600 Million by Oberland; Shares up Pre-Bell - marketscreener.com
Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Develo - GuruFocus
Biohaven Pharma (BHVN) Announces Investment up to $600 Million by Oberland Capital - StreetInsider
Biohaven Announces Investment up to $600 Million by Oberland Capital - PR Newswire
Biohaven (NYSE:BHVN) Upgraded at William Blair - Defense World
Biohaven (BHVN) Faces Market Setback After EMA Withdrawal - GuruFocus
Wells Fargo & Company MN Increases Stock Position in Biohaven Ltd. (NYSE:BHVN) - Defense World
Biohaven share price undervaluing pipeline potential, says RBC Capital - Yahoo Finance
Why Biohaven Stock Plummeted by More Than 15% Today - Yahoo Finance
Biohaven stock slides on withdrawal of European marketing application - BioPharma Dive
Biohaven (BHVN) Withdraws EMA Application, U.S. Approval Crucial - GuruFocus
Biohaven (BHVN) Withdraws Troriluzole Application in Europe, Foc - GuruFocus
Biohaven (BHVN) Stock Drops After Withdrawal of EU Drug Applicat - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Biohaven Ltd. Stock Faces Turbulence Amid Strategic Shifts - TipRanks
Biohaven Ltd (NYSE:BHVN) Shares Surged 25.27% In A Week – But Will They Keep Going Up? - Marketing Sentinel
Biohaven Pharma stock tumbles after withdrawal of Dazluma application in EU - Investing.com UK
BHVN’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Biohaven Ltd (BHVN) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Biohaven Ltd [BHVN] Director makes an insider purchase of 32,700 shares worth 1.0 million. - knoxdaily.com
Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21 - Insider Monkey
Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Stock Traders Buy Large Volume of Biohaven Call Options (NYSE:BHVN) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd.BHVN - PR Newswire
Biohaven Ltd (BHVN)’s stock rises to 20.55 per share - uspostnews.com
Biohaven Ltd (NYSE: BHVN) Shocks Wall Street This Week With A 0.88% Stock Price Incline - Marketing Sentinel
Biohaven (BHVN) Options Move Yields 15% Profit in a Day | BHVN S - GuruFocus
Biohaven Pharmaceutical : Announces Pricing Of $250 Million Public Offering Of Common Shares - marketscreener.com
LPL Financial LLC Raises Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Q1 Earnings Estimate for Biohaven Issued By Leerink Partnrs - Defense World
BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm - Finansavisen
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by Alliancebernstein L.P. - Defense World
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biohaven Ltd Azioni (BHVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Car Bruce | Chief Scientific Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
4,750 |
0 |
7,133 |
| Gentile Kimberly | SVP, Clinical Operations |
Jan 05 '25 |
Option Exercise |
0.00 |
3,750 |
0 |
99,719 |
| Clark George C. | VP, Chief Accounting Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
66,168 |
| Buten Matthew | Chief Financial Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
4,250 |
0 |
196,013 |
| Coric Vlad | Chief Executive Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
14,250 |
0 |
1,803,409 |
| CHILDS JOHN W | Director |
Dec 30 '24 |
Buy |
35.94 |
29,000 |
1,042,393 |
2,368,741 |
| CHILDS JOHN W | Director |
Oct 02 '24 |
Buy |
47.50 |
21,052 |
999,970 |
21,052 |
| Coric Vlad | Chief Executive Officer |
Oct 02 '24 |
Buy |
47.50 |
21,052 |
999,970 |
861,942 |
| Bailey Gregory | Director |
Sep 24 '24 |
Buy |
44.19 |
5,000 |
220,966 |
1,620,071 |
| CHILDS JOHN W | Director |
Jul 18 '24 |
Buy |
35.67 |
28,400 |
1,012,983 |
2,339,741 |
0.78%
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):